If the person or committee that must sign sits in market access, health economics and outcomes research, launch, medical affairs, or brand, use the pharma route. If the owner is a pathway committee or operator, use the protocol route.
Engagement options
Start with the route that matches who owns the decision.
The simplest way to choose is to look at who owns the decision, what is blocked, and what kind of brief the team needs. If you are unsure, start with the sample brief.
Both routes start with a concrete decision, not a broad discovery project.
Choose a route
Primary route
Open routePharma access and launch review
For market access, health economics and outcomes research, launch, medical affairs, and brand teams with a concrete access, launch, targeting, or evidence decision that already carries timing pressure.
Best when
One decision lead exists and delay already has cost.
Bring
The decision, the team, the stake, the approver, and the main blocker.
- A decision brief with current evidence, business impact, sign-off path, uncertainty, and a fallback plan. It is built to support medical, legal, regulatory, and other internal review, not replace it.
- Not for broad monitoring, generic landscape work, or a decision without a named owner.
Secondary route
Open routeProtocol and pathway review
For CMOs, governance leads, and operators responsible for cost, quality, or utilization carrying one delayed pathway or protocol decision with measurable downside.
Best when
The pathway, owner, and cost of waiting are already concrete enough to review now.
Bring
The blocked change, who owns it, and why approval is stuck.
- A review brief that clarifies readiness, safeguards, approval logic, and the re-review rule.
- Not for broad redesign work, workflow ownership first, or exploratory strategy without one bottleneck.
Fast sort
Choose the route in under a minute.
Use these three checks to decide where to start.
If the team cannot say exactly what needs to be decided, it is still too early. Both routes work best when the team can name the actual decision rather than a broad discovery project.
If the team cannot explain what would make it wait, narrow, or stop, the route is not ready. The brief has to carry that logic from the start.
Next step
Choose the route where the owner, the stakes, and the urgency are already clear.
Keep the first note short: the decision, the owner, the impact, who needs to approve it, and what is still unresolved. If the issue is still broad, narrow it before starting. Do not send PHI or patient-level data in the first note.